MedTrace Logo

Neutrophil FFA2/GPR43 Receptor Expression in Patients With the Diagnosis of Sepsis

NCT02699905 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2017-01-13

No results posted yet for this study

Summary

This study seeks to elucidate the quantitative expression of G - protein receptor 43/free fatty acid (GPR43/FFA2) receptors in patients with the diagnosis of sepsis and specifically, its expression as it relates to the severity of sepsis. The investigators hypothesize that patients with more severe sepsis, as defined by a higher SOFA (Sequential Organ Failure Assessment Score), will have decreased expression of the GPR43/FFA2 as compared to patients with lower SOFA scores, consistent with a less exuberant immune response to infection.

Patients admitted to Penn State Hershey Medical Center with a diagnosis of sepsis of any cause will undergo blood testing of leukocytes to determine the expressed quantity of GP43 during standardized time points of their illness and recovery. No interventions will be made in the standard clinical management of the patient. Additionally, healthy volunteers will be recruited to exam baseline GPR43 receptor expression between sepsis and control groups.

Conditions

  • Sepsis
  • Septic Shock
  • Multiple Organ Dysfunction
  • Intra-abdominal Sepsis

Interventions

OTHER

phlebotomy

phlebotomy

Sponsors & Collaborators

  • Milton S. Hershey Medical Center

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2017-08-31
Completion
2017-11-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02699905 on ClinicalTrials.gov